EHC/X
Oct 17, 2025, 08:28
EHC New Tech 2025: Join to Explore Advances in Bleeding Disorders Treatments
The European Haemophilia Consortium (EHC) shared on X:
”Just two weeks to the EHC New Tech 2025!
Join us on Oct 31–Nov 2 in Ljubljana to explore advances in Bleeding Disorders treatments.
Limited to EHC NMOs and HCPs—secure your spot!”
New products for bleeding disorders are expected to enter the European market in the future.
EHC New Tech 2025 will explore the underlying technologies of these innovations and examine strategies to ensure patient access—particularly focusing on their economic sustainability.
Don’t miss it! Register here.
Stay updated with Hemostasis Today.
-
Mar 6, 2026, 16:51Priya Reehal: Highlighting The Central Role of Nurses in Cardio-Oncology
-
Mar 6, 2026, 16:50Rainer Kaiser: Blinatumomab Shows Remarkable Response in Multi-Refractory ITP and APS
-
Mar 6, 2026, 16:18Laila Shalabi: Clopidogrel, Aspirin, and the Role of PPIs in Coronary Artery Disease
-
Mar 6, 2026, 16:17Paul McKenzie: The Value of Gene Therapy in Bleeding Disorders
-
Mar 6, 2026, 16:15Basma El Homasany: The ‘Little Brain’ of the Heart and Its Role in Health
-
Mar 6, 2026, 16:14Jamal Rana: Family History and Polygenic Risk for Coronary Heart Disease
-
Mar 6, 2026, 15:43Kristy Ainslie: Breaking Down the Discovery and FDA Approval of Drug Carriers
-
Mar 6, 2026, 15:18Claudio Laudani: Efficacy and Safety of Colchicine for Secondary Prevention in Coronary Artery Disease
-
Mar 6, 2026, 15:09Chris Simon: Persona PLUS Receives FDA Clearance for Patent‑Protected Plasma Apheresis